Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Baricitinib

FDA-approved product (tablet, oral), marketed as Baricitinib, Olumiant.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Baricitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Janus Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Baricitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Baricitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

    NCT05792462 · start 2023-04-15

    Registered record
    Registry ID
    NCT05792462
    Conditions
    NMO Spectrum Disorder
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2023-04-15
    Completion
    2027-03-01
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNMO Spectrum Disorder
    InterventionBaricitinib
    PhasePhase 1
    Registry statusActive not recruiting

  • Baricitinib for Refractory Takayasu Arteritis

    NCT06662721 · start 2023-04-03

    Registered record
    Registry ID
    NCT06662721
    Conditions
    Takayasu Arteritis
    Interventions
    Baricitinib 4 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-04-03
    Completion
    2024-06-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTakayasu Arteritis
    InterventionBaricitinib 4 MG
    PhasePhase 2
    Registry statusCompleted

  • Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.

    NCT07645430 · start 2023-01-01

    Registered record
    Registry ID
    NCT07645430
    Conditions
    Alopecia Areata
    Interventions
    Baricitinib 4 MG Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2026-06-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlopecia Areata
    InterventionBaricitinib 4 MG Oral Tablet
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy and Safety of Baricitinib in Sjogren's Syndrome

    NCT05016297 · start 2022-07-14

    Registered record
    Registry ID
    NCT05016297
    Conditions
    Sjogren's Syndrome
    Interventions
    Baricitinib; Hydroxychloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-07-14
    Completion
    2024-11-22
    Enrolment
    87

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSjogren's Syndrome
    InterventionBaricitinib; Hydroxychloroquine
    PhasePhase 2
    Registry statusCompleted

  • Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

    NCT05446831 · start 2022-07-13

    Registered record
    Registry ID
    NCT05446831
    Conditions
    ITP; Immune Thrombocytopenia
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-07-13
    Completion
    2023-12-01
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionITP; Immune Thrombocytopenia
    InterventionBaricitinib
    PhasePhase 2
    Registry statusUnknown

  • Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

    NCT05400889 · start 2022-06-10

    Registered record
    Registry ID
    NCT05400889
    Conditions
    Idiopathic Inflammatory Myopathies
    Interventions
    tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-06-10
    Completion
    2023-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Inflammatory Myopathies
    Interventiontofacitinib
    PhasePhase 2
    Registry statusUnknown

  • Use of Baricitenib to Maintain of Remission

    NCT05686746 · start 2022-06-01

    Registered record
    Registry ID
    NCT05686746
    Conditions
    Lupus or SLE; Nephritis
    Interventions
    Baricitinib 4 MG; Baricitinib 2 MG; MMF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2022-06-01
    Completion
    2023-08-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus or SLE; Nephritis
    InterventionBaricitinib 4 MG; Baricitinib 2 MG; MMF
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

    NCT05119452 · start 2022-03

    Registered record
    Registry ID
    NCT05119452
    Conditions
    Rheumatoid Arthritis
    Interventions
    Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-03
    Completion
    2024-09
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionDiscontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)
    PhaseNot applicable
    Registry statusUnknown

  • ConsideRAte Study - Splenic Stimulation for RA

    NCT05003310 · start 2021-10-19

    Registered record
    Registry ID
    NCT05003310
    Conditions
    Rheumatoid Arthritis
    Interventions
    Active Stimulation; Sham Stimulation; Baricitinib; Background Treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2021-10-19
    Completion
    2032-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionActive Stimulation; Sham Stimulation; Baricitinib; Background Treatment
    PhaseNot applicable
    Registry statusRecruiting

  • RA-PRO PRAGMATIC TRIAL

    NCT04692493 · start 2021-09-22

    Registered record
    Registry ID
    NCT04692493
    Conditions
    Rheumatoid Arthritis
    Interventions
    targeted synthetic DMARD class; non-TNFi-biologic class
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-09-22
    Completion
    2029-07-31
    Enrolment
    924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    Interventiontargeted synthetic DMARD class; non-TNFi-biologic class
    PhasePhase 3
    Registry statusRecruiting

  • Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo

    NCT04822584 · start 2021-07-16

    Registered record
    Registry ID
    NCT04822584
    Conditions
    Vitiligo
    Interventions
    Baricitinib Oral Product; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-07-16
    Completion
    2023-04-26
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionBaricitinib Oral Product; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of Efficacy of Different Treatment Regimens of Olokizumab

    NCT05187793 · start 2021-07-08

    Registered record
    Registry ID
    NCT05187793
    Conditions
    COVID-19
    Interventions
    Olokizumab; Standard therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-07-08
    Completion
    2023-04
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionOlokizumab; Standard therapy
    PhasePhase 3
    Registry statusUnknown

  • A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

    NCT04517253 · start 2020-10-27

    Registered record
    Registry ID
    NCT04517253
    Conditions
    Nakajo-Nishimura Syndrome; Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome; STING-Associated Vasculopathy With Onset in Infancy; Aicardi Goutieres Syndrome
    Interventions
    Baricitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2020-10-27
    Completion
    2024-11-28
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNakajo-Nishimura Syndrome; Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome; STING-Associated Vasculopathy With Onset in Infancy; Aicardi Goutieres Syndrome
    InterventionBaricitinib
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

    NCT05279391 · start 2020-10-25

    Registered record
    Registry ID
    NCT05279391
    Conditions
    COVID-19 Severe Respiratory Failure
    Interventions
    Dexamethasone; Low molecular weight heparin; Anakinra 100Mg/0.67Ml Inj Syringe; Tocilizumab; Baricitinib; Dornase Alfa Inhalant Product
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-10-25
    Completion
    2023-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19 Severe Respiratory Failure
    InterventionDexamethasone; Low molecular weight heparin; Anakinra 100Mg/0.67Ml Inj Syringe; Tocilizumab +2 more
    PhaseNot applicable
    Registry statusUnknown

  • Baricitinib Compared to Standard Therapy in Patients With COVID-19

    NCT04393051 · start 2020-05-20

    Registered record
    Registry ID
    NCT04393051
    Conditions
    Covid-19; SARS-CoV 2; SARS Pneumonia
    Interventions
    Baricitinib Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-05-20
    Completion
    2020-07-30
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid-19; SARS-CoV 2; SARS Pneumonia
    InterventionBaricitinib Oral Tablet
    PhasePhase 2
    Registry statusUnknown